Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2025
Business Overview: Vivos is a medical technology company developing non-surgical oral appliances and therapeutic treatments for obstructive sleep apnea (OSA) and dentofacial abnormalities. The company is currently pivoting its business model from a traditional VIP dentist enrollment strategy to a strategic alliance and acquisition model focused on owning and operating sleep centers.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $3,016 | $3,419 |
| Gross Profit | $1,509 | $1,937 |
| Gross Margin | 50% | 57% |
| Operating Loss | $(3,918) | $(3,785) |
| Net Loss | $(3,864) | $(3,763) |
| Net Loss Per Share (Basic/Diluted) | $(0.45) | $(1.63) |
| Cash and Cash Equivalents (End of Period) | $2,342 | $2,611 |
| Net Cash Used in Operating Activities | $(3,796) | $(2,516) |
| Total Liabilities | $6,875 | $7,330 |
| Stockholders' Equity | $4,407 | $7,954 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 12% ($403,000) year-over-year. This was driven primarily by a 75% drop in VIP enrollment service revenue ($223,000 vs. $907,000) due to the strategic pivot away from recruiting new dentists. Product revenue increased slightly by 8% ($139,000) due to higher volume in Guide sales.
- Margin Compression: Gross margin decreased from 57% to 50%, attributed to the shift in revenue mix toward lower-margin product sales and the reduction in high-margin service revenue.
- Expense Reduction: Sales and marketing expenses decreased by 45% ($297,000) due to reduced commissions and personnel costs associated with the VIP model. General and administrative expenses remained relatively flat.
- Liquidity Deterioration: Cash and cash equivalents declined by approximately $3.9 million during the quarter. The company reported a net cash burn of $3.8 million from operations.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt regarding the company's ability to continue as a going concern. With only $2.3 million in cash, the company states it does not have sufficient funds to operate for the next 12 months without additional financing.
- Strategic Pivot: The company is actively shifting resources to acquire and operate sleep centers. On April 15, 2025 (subsequent to the period end), Vivos entered into an agreement to acquire The Sleep Center of Nevada (SCN) for approximately $9 million in total consideration (cash, stock, and earn-out).
- Financing Needs: The company intends to secure debt or equity financing to fund the SCN acquisition and maintain operations. It is also seeking to raise capital to meet Nasdaq minimum stockholders' equity requirements ($2.5 million).
- Clinical Trials: A clinical study with Stanford University evaluating the DNA appliance vs. CPAP was placed on hold in late 2024 due to low patient recruitment.
- Legal Proceedings: Ongoing litigation with Ortho-Tain, Inc. regarding false advertising and trade practices remains pending in the Tenth Circuit Court of Appeals.
Investor Verification Checklist
- Cash Runway: Verify the timeline and terms of any new debt or equity financing required to fund the $6 million cash portion of the SCN acquisition and cover operating losses.
- Nasdaq Compliance: Monitor the company's ability to maintain the $2.5 million minimum stockholders' equity requirement to avoid delisting.
- Acquisition Closing: Confirm the closing conditions for the Sleep Center of Nevada acquisition, specifically the receipt of third-party consents and the quality of earnings report.
- Revenue Model Transition: Assess the timeline for the new strategic alliance model to generate sufficient revenue to offset the decline in VIP enrollment fees.
- Legal Exposure: Review the status of the Ortho-Tain litigation and potential financial impact of any adverse rulings.